Evaluating the Efficacy and Safety of of HSK44459 in Patients With Behçet's Disease

Summary

This is a phase 2, multi-center, randomised, double-blind, placebo-controlled study with an equal randomization among the HSK44459 dose 1, dose 2 and placebo treatment groups. The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.

Timeline

Start

2025-03-24

Primary completion

2026-06-05

Completion

2026-07-03

Drugs

Indications